Alternatively, as this study shows that RIP1 is essential for T-cell maintenance, targeting RIP1 in T cells could be used as a treatment for T-cell leukemia and lymphomas to induce apoptosis and reduce T-cell numbers. This evidence concerns the gene RIPK1 and T-cell leukemia.